KURA Shorts Hold Firm Into Thursday's Earnings Print

Kura Oncology heads into its November 9 earnings report with short interest entrenched at an elevated level, options traders turning more defensive by the day, and a wide gap between where the stock trades and what the Street thinks it is worth.

The clearest positioning signal right now is in the options market. Put/call ratio has climbed to 1.25, its highest reading of the past year, running almost two standard deviations above the 20-day average of 0.96. The move is not sudden. The ratio was below 0.80 as recently as mid-October, then began a steady climb that accelerated through the final week of the month. That is a consistent accumulation of downside protection, not a one-day spike, which makes it harder to dismiss.

Short interest adds to that cautious picture, though without the drama the options data might imply. Bears hold 16.4% of the free float short, up roughly 1.4% over the week and 2.1% over the month, a steady grind rather than a sudden conviction trade. FINRA's fortnightly figure put the official tally at 14.3 million shares with a days-to-cover of 8.6, confirming the position is real and would take nearly two weeks to unwind at normal volume. Borrow conditions are relaxed enough that this is not a forced situation: availability is wide at 703%, meaning there are roughly seven shares available to borrow for every one already on loan, and cost to borrow has actually eased over the past month to 0.36%. The lending market is not telling a squeeze story. Shorts have room and are paying very little for it.

The Street itself is bullish but the bulls have been waiting a while. Consensus is a Buy across the analyst panel, with a mean price target around $31.80, implying more than 200% upside from the current $9.88 price. JP Morgan initiated coverage in early October with an Overweight and a $30 target. Wedbush lifted its target to $38 in August after the Q2 print. That gap between current price and targets is not a data error; it reflects the market's scepticism about how fast the commercial story at KOMZIFTI can develop. The bull case centres on ziftomenib's clinical profile in NPM1-mutant AML, with KOMET-007 data showing 96% complete remission composite and 94% twelve-month overall survival, and a balance sheet carrying $519 million in cash. Bears point to competitive risk in a crowded AML space, dependence on biomarker identification, and the structural need for additional capital raises further down the development timeline. ORTEX factor scores lean toward the bear side of that debate: EPS momentum ranks in the 20th percentile on a 90-day basis, and the short score sits at 61.6, essentially flat over the past two weeks and consistent with elevated short pressure relative to peers.

Insider activity from late September adds a note of caution. The CCO, CMO, COO, CLO, and SVP of Finance and Accounting all filed open-market sales on September 28 and 29, together covering roughly 97,000 shares at prices around $10.50. None of the larger sales were declared under a 10b5-1 plan, aside from those filed by the COO and CLO. Discretionary selling by this many senior officers within a two-day window is worth noting, even if the individual dollar amounts are modest. The only buy in the recent record is a $184,500 option exercise by the Chief Scientific Officer on September 24, which is a compensation mechanism rather than an open-market purchase.

On the institutional register, Montanova Capital holds 9.6% and BVF Partners holds 9.5%, both the last reported as of June 30. BlackRock filed an updated 13G in late October, bringing its declared stake to 8.9% from 7.8% previously, the most recent ownership signal in the data and a marginal addition. No 13D activist is on the register.

The next five days resolve the most immediate tension: Kura reports after the close on November 9, and the past two earnings prints have produced meaningful moves. August's Q2 print delivered a 1.6% one-day move followed by a 26% five-day rally. The earlier May print moved 4% on the day and 9.7% over five days. Whether the defensive options positioning turns out to be well-timed or premature is what the report will decide.